| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 23, 2021 |
| Accession Number: | 0001104659-21-094658 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 23, 2021 |
| Accession Number: | 0001104659-21-094658 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
Oppenheimer upgraded Alexion Pharma from Perform to Outperform and set a new price target of $205.00
Credit Suisse resumed coverage of Alexion Pharma with a rating of Neutral and set a new price target of $190.00
SVB Leerink downgraded Alexion Pharma from Outperform to Mkt Perform
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 21, 2021 S&P 500 Addition Moderna MRNA Health Care S&P 500 Deletion Alexion Pharmaceuticals ALXN Health Care For more information about S&P Dow Jones Indices, please
– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met, with high statistical significance, its primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at Week 26, and for the s
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Honeywell International Inc. (NASDAQ:HON), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Wednesday, July 21, 2021. Honeywell International Inc. will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.honeywell.com/ . About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital ma
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,